
via CU Boulder
It’s ‘lights out’ for antibiotic-resistant superbugs as next-generation light-activated nanotech proves it can eradicate some of the most notorious and potentially deadly bacteria in the world.
Developed by the University of South Australia and published in Pharmaceutics, the new light therapy can eliminate antibiotic-resistant superbugs golden staph and pseudomonas aeruginosa by 500,000-fold and 100,000-fold respectively.
Golden staph (staphylococcus aureus) and pseudomonas aeruginosa are among the most deadly superbugs in the world. Globally, about 1.27 million people die as a result of antibiotic-resistant bacteria.
Lead researcher, UniSA’s Dr Muhammed Awad, says the new light therapy will be a game-changer for millions of people worldwide.
“Golden staph and pseudomonas aeruginosa are both highly transmissible bacteria, commonly found on people’s skin. But if they get into the blood, they can lead to sepsis or even death,” Dr Awad says.
“Patients in hospitals – particularly those with wounds or catheters, or those on ventilators – have a higher risk of getting these bacteria, and while antibiotics may help, their extensive use has led to waves of microbial resistance, often making them ineffective.
“Our photodynamic technology works differently, harnessing the energy of light to generate highly reactive oxygen molecules that eradicate microbial cells and kill deadly bacteria, without harming human cells.”
The researchers tested the antimicrobial photodynamic therapy on recalcitrant bacterial infections caused by antibiotic resistant strains of golden staph and pseudomonas aeruginosa.
Senior researcher, UniSA’s Professor Clive Prestidge, says that the technology has some key advantages over conventional antibiotics and other light therapies.
“The new therapy is created in an oil that that is painted on a wound as a lotion. When laser light is applied to the lotion, it creates reactive oxygen species which act as an alternative to conventional antibiotics,” Prof Prestidge says.
“Current photoactive compounds also suffer from poor water-solubility which mean that they have limited clinical application.
“Our approach uses food grade lipids to construct nanocarriers for the photoactive compound which improves its solubility and antibacterial efficiency far beyond that of an unformulated compound.
“These molecules target multiple bacterial cells at once, preventing bacteria from adapting and becoming resistant. So, it’s a far more effective and robust treatment.
“Importantly, the human skin cells involved in the wound healing process showed enhanced viability, while the antibiotic resistant bacteria were entirely eradicated.”
The consequences of not managing superbugs are high. Already, antibiotic resistant microbials cost millions of lives and trillions of dollars to the global economy each year.

“This technology is very promising and is gaining the attention of scientists worldwide,” Prof Prestidge says.
“The next step is to commence clinical trials and develop this technology further to be available in clinics. With the support of funding bodies, we hope that Australians will have access to this technology as soon as possible.”
Original Article: ‘Lights out’ for antibiotic-resistant superbugs
More from: University of South Australia
The Latest Updates from Bing News
Go deeper with Bing News on:
Antimicrobial photodynamic therapy
- Antimicrobial stewardship: Short-course antibiotic therapy
Ensuring antibiotics are used for an appropriate duration has the potential to reduce cost, improve patient outcomes and reduce antimicrobial resistance. There are multiple opportunities to advance ...
- Polyphenolic natural products as photosensitizers for antimicrobial photodynamic therapy: recent advances and future prospects
Antimicrobial photodynamic therapy (aPDT) has become a potent contender in the fight against microbial infections, especially in the context of the rising antibiotic resistance crisis. Recently, there ...
- Antimicrobial Photodynamic Therapy Suppresses Dental Plaque Formation in Healthy Adults: A Randomized Controlled Clinical Trial
In the groups treated with either LED or TBO alone, the numbers of CFUs did not differ from those of the untreated control. Conversely, groups that received TBO + LED exhibited numbers of CFUs ...
- Antimicrobial photodynamic therapy with erythrosine and blue light on dental biofilm bacteria: study protocol for randomised clinical trial
Introduction The objective is to investigate the effect of antimicrobial photodynamic therapy (aPDT) mediated by erythrosine and a blue light-emitting diode (LED) in the reduction of bacteria in ...
- New Advances in Biomedical Applications of Porphyrins and Analogs as Photosensitizers, Pro-oxidants, and Bioimaging Agents
Porphyrins and analogs are well-known for their roles in important biological functions, but also their medical applications among others. In general, these aromatic and highly conjugated macrocycles ...
Go deeper with Bing News on:
Light therapy
- The Transformative Wellness Benefits of Infrared Light Therapy
One emerging therapy that's gaining recognition for its holistic benefits is infrared light therapy. This innovative approach utilizes the healing power of infrared light to promote overall wellness, ...
- What Is Red Light Therapy?
As noted by Murphy-Rose, regular use of red light therapy reduces inflammation and ramp up both collagen production and collagen density, leading to improved skin texture and reduced wrinkles over ...
- NunaWave Red Light Therapy Wrap Reviewed – Scam Brand or Really Effective?
NunaWave is a red light therapy device designed to reduce pain with just minutes per day. By wrapping NunaWave around yourself daily, you can relieve muscle soreness, pain, arthritis, and more. The ...
- 'What I wish I knew before buying a red light therapy tool' reveals a beauty tech expert
In the market for a red light therapy device? Our Beauty Editor has a few pearls of wisdom to share on what makes a great anti-ageing tool before you make the splurge ...
- Can Light And Sound Therapy Treat Alzheimer’s Disease? Part 3
Cognito Therapeutics, an MIT-based neurotechnology company, made headlines this year when they announced a $73 million investment into a premier therapy for Alzheimer’s.